Clinical trial
MEN-10755 in Treating Patients With Solid Tumors
NCT00003982 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00003982 |
|---|---|
| Title | MEN-10755 in Treating Patients With Solid Tumors |
| Official title | Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed by One Week's Rest |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | sabarubicin |
| Enrollment | 30 |
| Start date | Jun 1, 1997 |
| First posted | May 25, 2004 |
| Last update posted | Jul 11, 2012 |
| Countries | Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: